Understanding the impact of glycosylation and keeping a close control on glycosylation of
product candidates are required for both novel and biosimilar monoclonal antibodies (mAbs) …

CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but
not stem or plasma cells. It is an ideal target for monoclonal antibodies (mAb), such as …

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given
in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto …

This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics
provides brief descriptions of the candidates, recently published clinical study results and on …

We analyzed in B-chronic lymphocytic leukemia (B-CLL) whole blood assays the activity of
therapeutic mAbs alemtuzumab, rituximab, and type II glycoengineered anti-CD20 mAb …

Anti-CD20 monoclonal antibodies (mAbs) are classified into type I (rituximab-like) or type II
(tositumomab-like) based on their ability to redistribute CD20 molecules in the plasma …

Monoclonal antibody (mAb) therapeutics are revolutionizing cancer treatment; however, not
all tumors respond, and agent optimization is essential to improve outcome. It has become …

Background Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-
dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated its …

Over the last few years, new generations of anti-CD20 monoclonal antibodies (mAbs) have
been developed for potential benefits over the classical, first-generation mAb rituximab …

Based on their mechanisms‐of‐action, CD 20 monoclonal antibodies (mA bs) are grouped
into Type I [complement‐dependent cytotoxicity (CDC) and antibody‐dependent cell …